news
EU marketing authorisation granted for rheumatoid arthritis treatment
Remsima SC™ is the world’s first subcutaneous formulation of infliximab and has been approved in the EU for the treatment of people with rheumatoid arthritis.
List view / Grid view
Rheumatoid arthritis (RA)
news
Data of rheumatoid arthritis treatment study released
New data shows the non-inferiority of efficacy for the subcutaneous (SC) formulation of CT-P13 to the intravenous (IV) formulation of CT-P13 in people with rheumatoid arthritis.
news
Seven medicines recommended for approval by EMA
The EMA CHMP has given a positive opinion for marketing authorisation approval to seven medicines following its October meeting.
article
Top 10 drugs by annual revenue in 2025
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
news
FTC investigates contracts regarding autoimmune disease drug, Remicade
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.
news
Phase III programme for the use of otilimab for rheumatoid arthritis launched
A Phase III clinical development programme testing otilimab in patients with RA has begun.
news
New drug delivery implant could treat patients remotely
Researchers have developed a new drug delivery system that can be remotely controlled to administer patients with medication.
news
Autoimmune disease research community gets boost from AMP RA/SLE study results
Data from the Phase I study of collaborative industry partnership AMP are now available, meaning scientists can benefit from access to important research about Rheumatoid Arthritis and Systemic Lupus Erythematosus.
news
Upadacitinib receives breakthrough therapy designation for atopic dermatitis
Phase 3 clinical program for upadacitinib in atopic dermatitis, the most common type of eczema, is planned to begin in the first half of 2018...
news
NICE recommends Lilly’s Baricitinib (Olumiant) to treat rheumatoid arthritis
Baricitinib is the first JAK inhibitor to be recommended by NICE to treat rheumatoid arthritis in adults who have not responded to conventional therapy…
news
EU approval for Regeneron and Sanofi’s rheumatoid arthritis drug
The European Commission (EC) has granted marketing authorisation for Regeneron and Sanofi’s Kevzara (sarilumab) for the treatment of rheumatoid arthritis...
news
Biologics before triple therapy not cost effective for rheumatoid arthritis
30 May 2017 | By American College of Physicians
Stepping up to biologic therapy offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs...
news
Sanofi and Regeneron receive CHMP positive opinion for rheumatoid arthritis treatment
28 April 2017 | By Niamh Marriott, Junior Editor
The European Medicine Agency's CHMP has adopted a positive opinion for the marketing authorisation of Sanofi and Regeneron Pharmaceuticals’ Kevzara...
news
Sandoz proposed biosimilars recommended for EU approval
25 April 2017 | By Niamh Marriott, Junior Editor
The Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions, separately recommending the approval of both Sandoz's (a Novartis division) biosimilar rituximab and biosimilar etanercept in Europe, to treat the same indications as their respective reference medicines.
article
2017 Pipelines: Drugs to watch
The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of more than $900 billion by 2021...
